DSDominique Salmon

Dominique Salmon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dominique Salmon has a total of 275 co-authors. Here are the top co-authors by number of shared publications:

  • Maria Patrizia Carrieri

    Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l’Information Médicale, ISSPAM, Marseille, France

    7 shared publications
  • Dorsaf Slama

    Department of Infectious Diseases, Villeneuve Saint Georges Hospital, Villeneuve Saint Georges, France

    6 shared publications
  • Fabienne Marcellin

    Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM Marseille France

    6 shared publications
  • Linda Wittkop

    Bordeaux Population Health Research Center INSERM U1219, Université de Bordeaux - ISPED, Bordeaux, France; INRIA SISTM, Talence, France; CHU de Bordeaux, Service d'information médicale, INSERM, Bordeaux, France

    6 shared publications
  • Dominique Batisse

    Infectious Disease Department, Hotel Dieu Hospital, Assistance Publique Hôpitaux de Paris (APHP), Paris Centre Hôtel-Dieu, 1 Place du Parvis de Notre-Dame, 75004 Paris, France

    3 shared publications
  • Nicolas Etienne

    Infectious Disease Department, Hotel Dieu Hospital, Assistance Publique Hôpitaux de Paris (APHP), Paris Centre Hôtel-Dieu, 1 Place du Parvis de Notre-Dame, 75004 Paris, France; University of Paris, Paris, France

    3 shared publications

Latest Publications

  • Open Access

    Formal and informal antimicrobial trade and usage in farmed animals of the urban area of Lomé, Togo

    by Esso-Tchella Madera Bodombossou, Komi Agbessi Adjessoklou, Rogatien Comlan Atoun, Isidore Tchaou, André Pouwedeou Bedekelabou, Dossou Zanou, Gad Boukaya, Camille Akapko, Laurence Armand Lefevre, Mounerou Salou, et al.

  • Open Access

    Endothelial Glycocalyx Anomalies and Ocular Manifestations in Patients with Post-Acute COVID-19

    by Georges Azar, Youssef Abdelmassih, Sophie Bonnin, Damien Guindolet, Vivien Vasseur, Francine Behar Cohen, Dominique Salmon, Martine Mauget-Faÿsse

    Objectives: To report ophthalmological and microvascular findings in patients with post-acute COVID-19. Methods: In this prospective, monocentric cohort study, we included patients with post-acute COVID-19 who presented with ophthalmological symptoms. All patients underwent indocyanine green angiography (ICGA), OCT, OCT-angiography, adaptive optics, and GlycoCheck assessments. Results: We included 44 patients, predominantly female (81.8%), with a mean age of 47.5 ± 11.5 years. Key ICGA findings revealed hyperreflective dots in 32 eyes (36.4%) and hemangioma-like lesions in 7 eyes (8.0%). Capillary non-perfusion in the superficial capillary plexus (SCP) and deep capillary plexus (DCP) was observed in 42 eyes (47.7%) and 21 eyes (23.9%), respectively. Eyes with hyperreflective dots exhibited a lower perfused boundary region (PBR), while those with superficial punctate keratitis showed a higher PBR (p = 0.02 and p = 0.002, respectively). Eyes with capillary non-perfusion in the SCP displayed lower capillary densities (CD4, CD5, and CD4-6; p = 0.001, 0.03, and 0.03, respectively), and eyes with non-perfusion in the DCP had lower CD4 (p = 0.03). A negative correlation was identified between capillary density and the wall-to-lumen ratio. Conclusions: Patients with post-acute COVID-19 demonstrate both retinal and choroidal vascular anomalies. Ocular pathology was associated with reduced capillary density. These injuries appear to stem more from microvascular disruptions than from persistent glycocalyx abnormalities.


  • Open Access

    The Prognostic Value of Olfactory Dysfunction in Patients with COVID-19: The COVIDORA Study

    by Anne-Laure Hamel, Léo Delbos, Pierre-André Natella, Thomas Radulesco, Mihaela Alexandru, Emmanuel Bartaire, Sophie Bartier, Gonda Benoite, Emilie Bequignon, Laurent Castillo, et al.

    Background: Among all studies describing COVID-19 clinical features during the first wave of the pandemic, only a few retrospective studies have assessed the correlation between olfac-tory dysfunction (OD) and the evolution of disease severity. The main aim was to assess whether OD is a predictive factor of COVID-19 severity based on the patient’s medical management (outpa-tient care, standard hospital admission, and ICU admission). Methods: A national, prospective, mul-ticenter cohort study was conducted in 20 public hospitals and a public center for COVID-19 screen-ing. During the first wave of the pandemic, from 6 April to 11 May 2020, all patients tested positive for COVID-19 confirmed by RT-PCR underwent two follow-up ENT consultations within 10 days of symptom onset. The main outcome measures were the evolution of medical management (out-patient care, standard hospital admission, and ICU admission) at diagnosis and along the clinical course of COVID-19 disease. Results: Among 481 patients included, the prevalence of OD was 60.7%, and it affected mostly female patients (74.3%) under 65 years old (92.5%), with fewer comor-bidities than patients with normal olfactory function. Here, 99.3% (290/292) of patients with OD presented with non-severe COVID-19 disease. Patients reporting OD were significantly less hospi-talized than the ones managed as outpatients, in either a standard medical unit or an ICU. Conclu-sions: As regards the clinical course of COVID-19 disease, OD could predict a decreased risk of hospitalization during the first wave of the pandemic.


  • Open Access

    Patients with Long COVID continue to experience significant symptoms at 12 months and factors associated with improvement: A prospective cohort study in France (PERSICOR)

    by Dominique Salmon, Dorsaf Slama, Françoise Linard, Nicolas Dumesges, Valérie Le Baut, Florence Hakim, Pauline Oustric, Emilie Seyrat, Patricia Thoreux, Esaie Marshall


  • Open Access

    Divergent adaptive immune responses define two types of long COVID

    by Jérôme Kervevan, Isabelle Staropoli, Dorsaf Slama, Raphaël Jeger-Madiot, Françoise Donnadieu, Delphine Planas, Marie-Pierre Pietri, Wiem Loghmari-Bouchneb, Motolete Alaba Tanah, Rémy Robinot, et al.

    Background: The role of adaptive immune responses in long COVID remains poorly understood, with contrasting hypotheses suggesting either an insufficient antiviral response or an excessive immune response associated with inflammatory damage. To address this issue, we set to characterize humoral and CD4+ T cell responses in long COVID patients prior to SARS-CoV-2 vaccination.Methods: Long COVID patients who were seropositive (LC+, n=28) or seronegative (LC-, n=23) by spike ELISA assay were recruited based on (i) an initial SARS-CoV-2 infection documented by PCR or the conjunction of three major signs of COVID-19 and (ii) the persistence or resurgence of at least 3 symptoms for over 3 months. They were compared to COVID patients with resolved symptoms (RE, n=29) and uninfected control individuals (HD, n=29).Results: The spectrum of persistent symptoms proved similar in both long COVID groups, with a trend for a higher number of symptoms in the seronegative group (median=6 vs 4.5; P=0.01). The use a highly sensitive S-flow assay enabled the detection of low levels of SARS-CoV-2 spike-specific IgG in 22.7% of ELISA-seronegative long COVID (LC-) patients. In contrast, spike-specific IgG levels were uniformly high in the LC+ and RE groups. Multiplexed antibody analyses to 30 different viral antigens showed that LC- patients had defective antibody responses to all SARS-CoV-2 proteins tested but had in most cases preserved responses to other viruses. A sensitive primary T cell line assay revealed low but detectable SARS-CoV-2-specific CD4 responses in 39.1% of LC- patients, while response frequencies were high in the LC+ and RE groups. Correlation analyses showed overall strong associations between humoral and cellular responses, with exceptions in the LC- group.Conclusions: These findings provide evidence for two major types of antiviral immune responses in long COVID. Seropositive patients showed coordinated cellular and humoral responses at least as high as those of recovered patients. In contrast, ELISA-seronegative long COVID patients showed overall low antiviral responses, with detectable specific CD4+ T cells and/or antibodies in close to half of patients (52.2%). These divergent findings in patients sharing a comparable spectrum of persistent symptoms raise the possibility of multiple etiologies in long COVID.


  • Open Access

    Population Pharmacokinetics of Orally Administered Clindamycin to Treat Prosthetic Joint Infections: A Prospective Study

    by Léo Mimram, Sophie Magréault, Younes Kerroumi, Dominique Salmon, Benjamin Kably, Simon Marmor, Anne-Sophie Jannot, Vincent Jullien, Valérie Zeller

    A population PK model of clindamycin orally administered to patients with prosthetic joint infections (PJIs) was developed using NONMEM 7.5. Monte-Carlo simulations were run to determine the probability of obtaining bone clindamycin concentrations equal to at least the MIC or four times the MIC for several MIC values and dosing regimens. One hundred and forty plasma concentrations prospectively obtained from 20 patients with PJIs were used. A one-compartment model with first-order absorption and elimination appropriately described the data. Mean PK-parameter estimates (F being the bioavailability) were: apparent clearance, CL/F = 23 L/h, apparent distribution volume, V/F = 103 l and absorption rate constant, Ka = 3.53/h, with respective interindividual variabilities (coefficients of variation) of 14.4%, 8.2% and 59.6%. Neither goodness-of-fit curves nor visual predictive checks indicated bias. The currently recommended 600 mg q8h regimen provided a high probability of obtaining concentrations equal to at least the MIC, except for MIC ≥ the clinical breakpoint for Staphylococcus spp. (0.25 mg/L). For such MIC values, higher daily doses and q6h regimens could be considered.


  • Open Access

    Smoking increases the risk of post-acute COVID-19 syndrome: Results from a French community-based survey

    by Hugues Barthélémy, Emmanuelle Mougenot, Martin Duracinsky, Dominique Salmon-Ceron, Jennifer Bonini, Fabienne Péretz, Olivier Chassany, Patrizia Carrieri

    Introduction: We aimed to estimate the prevalence and incidence of specific symptoms and predictors of post-acute COVID-19 syndrome using data collected from an anonymous online survey. Methods: We included adult participants with symptoms ≥60 days (D60+), fulfilling the World Health...


  • Open Access

    Screening for SARS-CoV-2 persistence in Long COVID patients using sniffer dogs and scents from axillary sweats samples

    by Dominique Grandjean, Dorsaf Slama, Capucine Gallet, Clothilde Julien, Emilie Seyrat, Marc Blondot, Maissa Benazaziez, Judith Elbaz, Dominique Salmon

    Objectives: Dogs can be trained to identify several substances not detected by humans, corresponding to specific volatile organic compounds (VOCs). The presence of VOCs, triggered by SARS-CoV-2 infection, was tested in sweat from Long COVID patients. Patients and methods: An axillary sweat sample of Long COVID patients and of COVID-19 negative, asymptomatic individuals was taken at home to avoid any hospital contact. Swabs were randomly placed in olfaction detection cones, and the material sniffed by at least 2 trained dogs. Results: Forty-five Long COVID patients, mean age 45 (6-71), 73.3% female, with prolonged symptoms evolving for a mean of 15.2 months (5-22) were tested. Dogs discriminated in a positive way 23/45 (51.1%) Long COVID patients versus 0/188 (0%) control individuals (p<.0001). Conclusion:This study suggests the persistence of a viral infection in some Long COVID patients and the possibility of providing a simple, highly sensitive, non-invasive test to detect viral presence, during acute and extended phases of COVID-19.


  • Post‐HCV cure self‐reported changes in physical activity, eating behaviours, and fatigue in people living with HIV (ANRS CO13 HEPAVIH)

    by Fabienne Marcellin, Vincent Di Beo, Laure Esterle, Sophie Abgrall, Gilles Pialoux, Tangui Barré, Linda Wittkop, Dominique Salmon-Ceron, Philippe Sogni, Patrizia Carrieri, et al.


  • Clinical, virological and imaging profile in patients with prolonged forms of COVID-19: A cross-sectional study

    by Dominique Salmon-Ceron, Dorsaf Slama, Thomas De Broucker, Marina Karmochkine, Juliette Pavie, Emmanuel Sorbets, Nicolas Etienne, Dominique Batisse, Gabriela Spiridon, Valérie Le Baut, et al.